US FDA explains how drug makers can meet new pediatric study plan requirement
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued draft guidance on how drug sponsors can meet a new rule that requires manufacturers subject to the Pediatric Research Equity Act to submit a pediatric study plan (PSP) early on in the drug development process1.